LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 39 filers reported holding LYRA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,525,776 | -3.4% | 1,413,242 | 0.0% | 1.04% | +38.0% |
| Q2 2023 | $5,717,732 | +42.4% | 1,413,242 | -29.2% | 0.76% | +86.5% |
| Q1 2023 | $4,013,914 | -40.7% | 1,996,972 | -7.4% | 0.41% | +16.0% |
| Q4 2022 | $6,773,916 | -46.1% | 2,157,298 | -14.1% | 0.35% | -51.9% |
| Q3 2022 | $12,577,000 | -13.6% | 2,510,302 | -2.6% | 0.73% | -13.8% |
| Q2 2022 | $14,556,000 | +595.5% | 2,576,196 | +394.9% | 0.84% | +1142.6% |
| Q1 2022 | $2,093,000 | -7.2% | 520,544 | +0.6% | 0.07% | -17.1% |
| Q4 2021 | $2,255,000 | -53.7% | 517,244 | -3.0% | 0.08% | -44.6% |
| Q3 2021 | $4,867,000 | +11.7% | 533,417 | -1.7% | 0.15% | +8.8% |
| Q2 2021 | $4,357,000 | +71.9% | 542,644 | +139.4% | 0.14% | +3.8% |
| Q3 2020 | $2,535,000 | +12.9% | 226,703 | +14.5% | 0.13% | -39.4% |
| Q2 2020 | $2,245,000 | – | 198,011 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,777,251 | $3,572,275 | 0.74% |
| Perceptive Advisors | 9,146,730 | $18,384,927 | 0.54% |
| PURA VIDA INVESTMENTS, LLC | 1,996,972 | $4,013,914 | 0.41% |
| VR Adviser, LLC | 924,170 | $1,857,582 | 0.36% |
| Nantahala Capital Management | 2,220,830 | $4,463,868 | 0.34% |
| Ikarian Capital, LLC | 343,685 | $711,427 | 0.16% |
| Soleus Capital Management, L.P. | 592,417 | $1,190,758 | 0.12% |
| Clearline Capital LP | 119,128 | $239,448 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 146,800 | $303,876 | 0.01% |
| Tower Research Capital LLC (TRC) | 9,972 | $20 | 0.00% |